Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Accumulated Expenses (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Accumulated Expenses for 4 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses changed N/A year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $6.0 million, down 47.68% over the prior year.
  • Accumulated Expenses was $2.1 million for Q3 2025 at Atara Biotherapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.7 million in Q4 2022 and bottomed at $641000.0 in Q2 2023.
  • Average Accumulated Expenses over 4 years is $9.2 million, with a median of $7.8 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses plummeted 96.07% in 2023, then surged 1034.01% in 2024.
  • Year by year, Accumulated Expenses stood at $17.7 million in 2022, then crashed by 34.77% to $11.5 million in 2023, then crashed by 47.68% to $6.0 million in 2024, then plummeted by 65.7% to $2.1 million in 2025.
  • Business Quant data shows Accumulated Expenses for ATRA at $2.1 million in Q3 2025, $2.6 million in Q2 2025, and $4.6 million in Q1 2025.